Shots:Health Canada has approved label expansion for Ixchiq against CHIKV disease in individuals (≥12yrs.)Approval was based on a P-III trial of Ixchiq vs PBO in adolescents over 6mos., which showed a superior high & sustained immune response in 99.1% of participants; data was published in The Lancet Infectious DiseasesAdditionally, label extension filing…
